Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2003 Apr 19;326(7394):835-6.
doi: 10.1136/bmj.326.7394.835.

Treatment of pulmonary hypertension

Andrew J Peacock; National Pulmonary Hypertension Services of UK and Ireland
Editorial

Treatment of pulmonary hypertension

Andrew J Peacock et al. BMJ. .
No abstract available

PubMed Disclaimer

References

    1. Newman JH, Wheeler L, Lane KB, Loyd E, Gaddipati R, Phillips JA, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med. 2001;345:319–324. - PubMed
    1. Machado RD, Paucilo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet. 2001;68:92–102. - PMC - PubMed
    1. Rich S, Kaufmann E, Levy PS. The effects of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76–81. - PubMed
    1. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesh DB, et al. A comparison of continuous intravenous epoprostenol (epoprostenol) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–302. - PubMed
    1. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long term epoprostenol (epoprostenol) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338:273–277. - PubMed

Publication types

MeSH terms